ACADIA Pharmaceuticals stock has a USD 31.34 consensus target from 18 analysts

Published on 10/17/2026 at 20:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 308.00 million, up 16.40 percent year over year. ACADIA Pharmaceuticals stock closed at USD 19.12 on October 16, 2026, down 2.99 percent.

Analyst view and reporting date

The October 14, 2026 consensus target was USD 31.34 from 18 analysts.
Second-quarter revenue reached USD 308.00 million, up 16.40 percent year over year.
ACADIA Pharmaceuticals stock closed at USD 19.12 on October 16, 2026, down 2.99 percent versus the prior close.
The next estimated earnings date is November 4, 2026.

ACAD, US0042251084, Illustration mit AI erstellt.

ACADIA Pharmaceuticals stock has a USD 31.34 average 12-month target from 18 analysts, according to MarketBeat on October 14, 2026. Against the October 16 closing price, that target is 63.91 percent above the stock. ACADIA Pharmaceuticals stock closed at USD 19.12 on October 16, 2026 at 4:00 p.m. EDT, down 2.99 percent from the prior close.

Revenue reached USD 308.00 million

ACADIA reported USD 308.00 million in second-quarter 2026 revenue, up 16.40 percent from the same quarter a year earlier. Adjusted earnings per share reached USD 0.18, above the USD 0.07 consensus estimate, according to MarketBeat.

Price position after October 16

The Nasdaq close stood 3.97 percent above ACADIA's 52-week low of USD 18.39 and 38.21 percent below its 52-week high of USD 30.96. The stock's year-to-date performance was minus 28.42 percent, while volume reached 1,672,142 shares against an average of 1,861,335 shares.

Valuation and November 4 date

ACADIA carried a market capitalization of USD 3.3 billion and a trailing price-to-earnings ratio of 8.61 on October 16, 2026. The company does not pay a dividend. Yahoo Finance lists November 4, 2026 as the estimated next earnings date.

Comparison with peers

ACADIA Pharmaceuticals (Nasdaq, USD): minus 2.99 percent, P/E 8.61, market capitalization USD 3.3 billion.

BioMarin Pharmaceutical (Nasdaq, USD): minus 2.44 percent, P/E 140.21, market capitalization USD 10.6 billion.

Minerva Neurosciences (Nasdaq, USD): minus 2.89 percent, P/E minus 0.08, market capitalization USD 112.2 million.

The next checkpoint is November 4

ACADIA develops medicines for neurological and rare diseases, with commercial products including NUPLAZID and DAYBUE, according to the company's investor-relations page. The November 4 earnings date gives the market its next scheduled result to compare with the USD 308.00 million quarterly revenue base.